Zhitong Finance App News, Yuanda Pharmaceutical (00512.HK) announced that recently, the Group completed the first patient enrollment in a phase II clinical study of GPN01020, an innovative traditional Chinese medicine drug used in preventive treatment of migraine in China. The study was a randomized, double-blind, placebo-controlled, multicenter phase II clinical study involving 180 migraine patients to evaluate the efficacy, safety, and tolerability of GPN01020 compared to placebo in preventing migraine attacks (hemorrhagic blockade). The completion of this clinical study to enroll the first patient is a major milestone in the Group's proprietary Chinese medicine sector.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.